Skip to main content
. 2015 May 24;6(25):21379–21394. doi: 10.18632/oncotarget.4091

Figure 8. In vivo anticancer efficacy of GS25 and GS25NP.

Figure 8

A. Nude mice bearing PC3 xenograft tumors were treated with GS25 (100 mg/kg) or GS25NP (20 and 100 mg/kg) by oral administration 5 days/week for 4 weeks. The control mice received vehicle only or void nanoparticles. B. At the end of the experiments, representative tumors were removed and photographed. C. All mice were monitored for changes in body weight as a surrogate marker of toxicity. Tumors were excised and cut into multiple sections for D. Western blotting for the protein expression of MDM2, Bax and PARP, where the intensity ratio under each band was obtained by IMAGEJ software analysis normalized on untreated control; and E. MDM2 immunohistochemical staining and TUNEL staining. The concentration unit for GS25NP is GS25 equivalent in all experiments.